Results 251 to 260 of about 1,669,550 (354)

Identifying a novel region in the Tembusu virus NS5 protein antagonizing type I interferon signaling. [PDF]

J Virol
Zhang J, Fan Y, An D, Mao M, Guo Z, Yang J, Li Q, Zhu S, Li G, Chen X, Zhou Z, Hou S, Diao Y, Tang Y.   +13 more
europepmc   +1 more source

Efferocytosis‐Driven Polyamine Metabolism in Macrophages Enhances Cancer Stem Cell Enrichment after Chemotherapy in Ovarian Cancer

Advanced Science, EarlyView.
Chemotherapy‐induced efferocytosis drives ovarian cancer stem cell enrichment. By engulfing apoptotic cancer cells, macrophages upregulate ODC1 and produce putrescine, which elevates osteopontin (OPN) expression. Secreted OPN then activates the CD44 receptor on cancer cells, promoting stemness and chemoresistance.
Wenhan Li, Feiquan Ying, Xinkai Pang, Qiulei Wu, Guoqing Li, Lin Huang, Jiayu Xin, Xiaoli Liu, Pan Liu, Xiaohan Xu, Shuran Tan, Yumei Gao, Tong Liu, Si Sun, Xiaoman Wang, Yiping Wen, Liqiong Cai, Shi Du, Yuan Zhang, Jing Cai   +19 more
wiley   +1 more source

Crimean-Congo hemorrhagic fever virus NSm protein inhibits the type I interferon signaling by binding to STAT2. [PDF]

PLoS Negl Trop Dis
Yoshikawa R, Sakurai Y, Kondo S, Kimura M, Yasuda J.   +4 more
europepmc   +1 more source

A Rationally Engineered Spleen‐Tropic One‐Component Lipid‐mRNA Complex (OncoLRC) for Cancer Vaccines

Advanced Science, EarlyView.
OncoLRC, a one‐component lipid‐mRNA complex, enables efficient spleen‐targeted delivery at an exceptionally low lipid‐to‐mRNA mass ratio (1.5:1), robustly activates immune responses, inhibits tumor growth, and synergizes with checkpoint blockade, presenting a next‐generation platform for mRNA vaccines.
Qimeng Yin, Chenchen Zhang, Jiahao Li, Kun Huang, Min Qiu   +4 more
wiley   +1 more source

Histopathological Alterations and Dysregulation of Type I Interferon Signaling in the Human Cerebral Cortex During Severe Dengue. [PDF]

J Med Virol
Castro LM, Fernandes ER, Quaresma JAS, Lancelotti CLP, Duarte MIS, Carvalho LV, Penny R, Vasconcelos PFDC, Mello ES, Sotto MN, Pagliari C.   +10 more
europepmc   +1 more source

Immune horses rapidly increase antileukoproteinase and lack type I interferon secretion during mucosal innate immune responses against equine herpesvirus type 1

Camille M. Holmes, Susanna Babasyan, Naya A. Eady, Christiane L. Schnabel, Bettina Wagner   +4 more
openalex   +1 more source

The Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon Production by Interfering with TRIM25-Mediated RIG-I Ubiquitination

Journal of Virology, 2017
Yong Hu, Wei Li, Ting Gao, Yan Cui, Yanwen Jin, Ping Li, Q. Ma, Xuan Liu, C. Cao   +8 more
semanticscholar   +1 more source

Spatial Profiling Reveals Distinct Molecular and Immune Evolution of Mouse Lung Adenocarcinoma Precancers with or Without Carcinogen Exposure

Advanced Science, EarlyView.
Tumor evolution in lung adenocarcinoma is shaped by genetic alterations and spatial immune dynamics. By integrating whole‐exome sequencing, imaging mass cytometry, and spatial transcriptomics across two mouse models, this study reveals how mutational burden, immune infiltration, and cell–state interactions evolve during early and late carcinogenesis ...
Bo Zhu, Muhammad Aminu, Pingjun Chen, Jian‐Rong Li, Chuanpeng Dong, Chenyang Li, Yanhua Tian, Shao‐Wei Lu, Hong Chen, Chenxi Ma, Xin Hu, Jie Ye, Andrew Y. Liu, Beibei Huang, Frank R. Rojas, Parra Cuentas. Edwin Roger, Ou Shi, Monique B. Nilsson, Alissa Poteete, Khaja B. Khan, Wei Lu, Luisa M. Solis Soto, Junya Fujimoto, Cara Haymaker, Ignacio I. Wistuba, Zhubo Wei, Linghua Wang, Don L. Gibbons, Ken Chen, Alexandre Reuben, Jason M. Schenke, John V. Heymach, Chao Cheng, Jia Wu, Jianjun Zhang   +34 more
wiley   +1 more source

PARP7 and aryl hydrocarbon receptor differentially regulate mammary cancer cell proliferation and STING-induced type I interferon signalling. [PDF]

Cell Oncol (Dordr)
Olafsen NE, Åhrling SS, Rasmussen M, Erlingsson LAM, Granly EN, Takaoka A, Matthews J.   +6 more
europepmc   +1 more source

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.

The Lancet Rheumatology, 2019
R. Furie, E. Morand, I. Bruce, S. Manzi, K. Kalunian, E. Vital, Theresa Lawrence Ford, Ramesh C. Gupta, F. Hiepe, M. Santiago, P. Brohawn, A. Berglind, R. Tummala   +12 more
semanticscholar   +1 more source